A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN )

Documents similaires

• Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
  par: Fei Gao, et autres
  Publié: (2026)
• Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
  par: Yingying Xiang, et autres
  Publié: (2024)
• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  par: Soo Lim, et autres
  Publié: (2024)
• Efficacy and safety of imeglimin add‐on to DPP ‐4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double‐blind FAMILIAR trial
  par: Kohei Kaku, et autres
  Publié: (2025)
• Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
  par: Leili Gao, et autres
  Publié: (2024)